In agreement with our findings with carebastine in MDA-MB-231 and MCF7 cells, these drug strategies also have potential for broader application to boost NIS function in non-thyroidal settings, including the radioiodide treatment for breast cancer in which NIS expression is typically induced in ∼70%–80% of cases (Tazebay et al., 2000). This evidence concerns the gene SLC5A5 and breast carcinoma.